Vera Therapeutics (VERA) investor relations material

Executive summary

• Atacicept advanced in pivotal Phase 3 trial for IgAN, meeting primary efficacy endpoint with significant reduction in proteinuria and favorable safety profile; BLA submitted and granted FDA priority review with PDUFA date set for July 7, 2026.

• Preparations for a potential U.S. commercial launch of atacicept are underway for mid-2026, pending approval, with executive team strengthened to support commercialization.

• Pipeline includes MAU868 (Phase 2 complete for BKV infections) and VT-109 (preclinical dual BAFF/APRIL inhibitor); no products approved or revenue from product sales to date.

• Executive team expanded with new Chief Commercial Officer, Chief Legal Officer, and Board member.

• Net loss for Q1 2026 was $121.0 million, up from $51.7 million in Q1 2025, reflecting increased R&D and G&A expenses as company prepares for potential commercialization.

Financial highlights

• Cash, cash equivalents, and marketable securities totaled $596.8 million as of March 31, 2026, down from $714.6 million at year-end 2025.

• Research and development expenses rose 108% year-over-year to $86.0 million, driven by higher drug manufacturing, milestone payments, and clinical trial costs.

• General and administrative expenses increased 146% year-over-year to $39.1 million, mainly due to higher headcount and commercial planning for atacicept.

• Operating expenses rose to $125.1 million in Q1 2026, up 119% year-over-year.

• Net cash used in operating activities was $106.5 million in Q1 2026.

Outlook and guidance

• Management expects continued net losses and negative cash flows for several years as pipeline advances and commercial infrastructure is built.

• Existing cash resources expected to fund operations and capital expenditures for at least the next 12 months and through potential approval and commercial launch of atacicept.

• Substantial additional funding will be required to support ongoing development, regulatory, and commercialization activities.

• Anticipates FDA accelerated approval of atacicept in IgAN by July 7, 2026, with U.S. commercial launch expected mid-2026, pending approval.

• Initial results from the PIONEER Phase 2 basket trial expected in Q2 2026; pivotal two-year eGFR data from ORIGIN 3 trial expected Q1 2027.